Electronic Study for Anastrozole Pharmacovigilance Evaluation (E-SAFE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00558168
First received: November 13, 2007
Last updated: July 25, 2008
Last verified: July 2008
  Purpose

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer


Condition
Early Breast Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Electronic Study for Anastrozole Pharmacovigilance Evaluation

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 1850
Study Start Date: January 2004
Study Completion Date: July 2008
  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion Criteria:

  • Metastatic breast cancer patients, previous hormonal therapy, other malignancies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00558168

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Nejdet Uskent Kadir Has University Medical School
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00558168     History of Changes
Other Study ID Numbers: ARI-IPEP-0104
Study First Received: November 13, 2007
Last Updated: July 25, 2008
Health Authority: Turkey: Turkish Republic Ministry of Health

Keywords provided by AstraZeneca:
Anastrazole
safety
early breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Anastrozole
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014